Acrivon Therapeutics, Inc. (ACRV) स्टॉक विश्लेषण

कंपनी का अवलोकन

Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to discovering and developing oncology medicines for patients with tumors predicted to be sensitive to specific treatments. The company leverages its proprietary generative phosphoproteomics platform, which is utilized within its Acrivon Predictive Precision framework to identify therapeutic sensitivities. This biotechnology firm functions within the broader Healthcare sector, specifically focusing on the Biotechnology industry where innovation drives the development of novel drug candidates. The company's market capitalization stands at $60.05M, supported by a workforce of 74 employees, while its reported annual revenue is not available in the current reporting period. These valuation and scale metrics indicate that the firm is a small-cap entity with limited historical revenue data, suggesting it is in an early stage of commercialization where market cap reflects the potential of its pipeline rather than established sales performance.

वित्तीय स्वास्थ्य

The financial statements for the trailing twelve months reveal a net income of $-77,905,000 and an EBITDA of $-82,758,000, with revenue figures not disclosed in the available data. The significant gap between the unreported revenue and the substantial net loss highlights a cost structure dominated by research and development expenditures rather than operational overhead associated with sales and marketing. The company reports a free cash flow of $-39,543,248, which indicates a continuous burn rate typical for clinical-stage biotechs that have not yet achieved commercial revenue milestones. Analysis of the three primary margins shows a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%, reflecting the current lack of profit generation from sales activities. In terms of liquidity, the company holds $118.58M in cash against $2.71M in debt, resulting in a debt-to-equity ratio of 2.41, which suggests a balance sheet that is currently leveraged relative to equity but possesses significant cash reserves to fund operations. The current ratio is recorded at 7.69, indicating a strong short-term liquidity position where current assets significantly exceed current liabilities. Return on Equity stands at -53.9% and Return on Assets is -32.2%, metrics that reveal management is currently deploying capital to generate losses typical for the development phase rather than generating immediate returns.

मूल्यांकन आकलन

Valuation multiples for the company include a trailing P/E ratio of N/A and a forward P/E of -0.83, implying that earnings are currently negative and traditional profitability-based valuation models are not applicable at this stage. The price-to-book ratio is 0.44, which indicates that the stock is trading at a discount relative to its book value, a common characteristic for small-cap biotechnology firms with intangible asset-heavy balance sheets. Alternative valuation metrics such as the price-to-sales ratio (N/A) and the EV/EBITDA of 0.67 provide additional context, though the EV/EBITDA figure is influenced by the high cash balance and negative earnings. The stock has traded between a 52-week high of $3.56 and a 52-week low of $1.05, meaning the current price point sits somewhere within this wide range, reflecting the high volatility of the sector. The beta value is 1.74, which signifies that the stock's price volatility is substantially higher than the broader market, exposing investors to greater price swings relative to a standard market index.

Growth & Income

Revenue growth year-over-year is not available, and earnings growth year-over-year is also N/A, preventing a direct comparison of the speed at which earnings are changing relative to revenue growth. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, indicating that the firm reinvests all available resources into its drug development pipeline rather than distributing income to shareholders. The overall growth and income profile is characterized by a lack of current profitability and dividend distributions, relying entirely on the conversion of its $118.58M cash reserve into future commercial products. This profile is consistent with clinical-stage biopharmaceutical companies that prioritize capital allocation toward research over immediate shareholder returns or income generation.